Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 20/20 | 0.92 |
| ▸ | IDH2 | P48735 | 10/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599349 | 1.00 | IDH1 (0.92) | IDH1IDH2 | |
| SCHEMBL17971621 | 1.00 | IDH1 (0.92) | IDH1IDH2 | |
| SCHEMBL17971623 | 1.00 | IDH1 (0.92) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393169 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL17971596 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL18748592 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL29599150 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393139 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL29422965 | 0.96 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393055 | 0.96 | IDH1 (1.00) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111527076-A | Co-crystals, pharmaceutical compositions thereof, and methods of treatment involving the same | 安吉奥斯医药品有限公司 | 2020-08-11 | — | — | CN | claimed |
| US-11851417-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-11345677-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-11345677-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210198234-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | LES LABORATOIRES SERVIER (FR) | 2021-07-01 | — | — | US | disclosed |
| US-20210198234-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | LES LABORATOIRES SERVIER (FR) | 2021-07-01 | — | — | US | disclosed |
| US-20210046081-A1 | METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY | SERVIER PHARMACEUTICALS LLC | 2021-02-18 | — | — | US | disclosed |
| EP-3704101-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | Agios Pharmaceuticals, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| CN-111527076-A | Co-crystals, pharmaceutical compositions thereof, and methods of treatment involving the same | 安吉奥斯医药品有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579324-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198234-A1 | COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF TREATMENT INVOLVING SAME | TP53, HCCS, LPXN | IDH1 87/4885IDH2 179/4885 |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-11851417-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | TP53, HCCS, LPXN | IDH1 87/4885IDH2 179/4885 |
| US-11345677-B2 | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | TP53, HCCS, LPXN | IDH1 87/4885IDH2 179/4885 |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
| US-20210046081-A1 | METHODS OF TREATING BRAIN TUMORS USING COMBINATION THERAPY | MGMT, PYGB, VHL | IDH1 27/4885IDH2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.